For example,
Antipneumococcal vaccination adults: second vaccine:
Health authorities are currently in depth the vaccination policy against invasive pneumococcal infections. However, especially in adults and are pronounced in the place of a new vaccine: Capvaxive, of MSD. However,
Today. Nevertheless, the French strategy recommends vaccination against pneumococcal infection with a single dose of Prevenar 20 (VPC 20) in adults at risk of serious form from the age of 18, indication for which this vaccine is reimbursed. Furthermore, In January 2025. Consequently, the High Authority for Health (HAS) recommended to expand this vaccination to all adults aged 65 and over, regardless of their level of risk. However. this extension is not yet effective: it will become it when the vaccine is taken care of by health insurance for this population, which supposes a publication in the “Official Journal”. According to Pfizer, it could occur during the summer. In antipneumococcal vaccination adults: second vaccine the meantime, pharmacists can only prescribe and administer Prevenar 20 in adults with comorbidities.
At the same time. HAS has just made an opinion on another vaccine indicated in the prevention of invasive pneumococcal infections in adults: CAPVAXIVE (VPC 21), developed by MSD. This vaccine, which obtained an AMM in Europe in March 2025, is not yet marketed in France.
When this vaccine is available, what will be its place in the vaccination strategy? The HAS. which examined the subject, believes that the CAPVAXIVE vaccine can be used, in the same way as Prevenar 20 in the current pneumococcal infections in fuels at risk from 18 years old, and soon in adults 65 and over with or without risk factors.
In its opinion. the HAS does not favor any of the two vaccines at this stage, even if Capvaxive seems better suited to the circulating serotypes affecting antipneumococcal vaccination adults: second vaccine seniors. This vaccine contains 21 serotypes (including 11 in common with Prevenar and 10 exclusive to VPC 21). In France, it would cover 84 % of pneumococcal serotypes responsible for bacteremia and 81 % of those responsible for meningitis, compared to 63.5 % and 56 % respectively for Prevenar 20 (according to 2022 data from the National Pneumococcal reference center).
In clinical studies. CAPVAXIVE has shown a non -lower immune response on common serotypes, and higher on the majority of its own serotypes, with a good safety profile. The undesirable effects were generally mild and transient, comparable to those observed with existing vaccines. No particular security signal has been noted, including after more than a million doses administered internationally.
In addition, the HAS believes that Capvaxive can be administered at the same time as the antigripping vaccine. However, no data is still available regarding co-administration with other vaccines antipneumococcal vaccination adults: second vaccine recommended in seniors (COVID-19, DTP, VRS, ZONA). HAS does not recommend a dose of recall at this stage. and is not yet pronounced on the interchangeability between Prevenar 20 and Capvaxive. Additional studies are therefore necessary to document its long -term efficiency and integration into an extended vaccine strategy.
Antipneumococcal vaccination adults: second vaccine
Further reading: Summary drugs: the drug agency alerts on new molecules close to benzodiazepines – Weight loss facilitates cell renewal – Coma, memory loss … An alert launched on nine new molecules – The Akdital Foundation deploys its medical caravans in Dakhla – Cases of measles in the United States are reaching their highest level since the official eradication of the disease.